---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-133332"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:09:45.619316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026

## Summary
- Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.
- Cash $58M at Dec 31; pro forma cash ~$274M after $230M oversubscribed equity offering closed Feb 2026.
- Phase 3 SELVA for microcystic LMs met primary endpoint (p<0.001); NDA submission on track for H2 2026.
- Phase 3 trial for cutaneous venous malformations planned H2 2026; Phase 2 for angiokeratomas in Q2 2026.
- Company to announce fourth QTORIN rapamycin indication and third platform product in H2 2026.

## SEC filing metadata
- accession: 0001193125-26-133332
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/0001193125-26-133332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-133332
- JSON: https://secwatch.observer/filing/0001193125-26-133332.json
- Plain text: https://secwatch.observer/filing/0001193125-26-133332.txt

## Key facts
- Earnings Releases
  PALVELLA THERAPEUTICS, INC. reported financial results for full year ending December 31, 2025.
  - Period: full year ending December 31, 2025
  - Result: reported results
  source text: On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/0001193125-26-133332-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.